Tag Archives: Aethlon Medical

Aethlon Medical reported early findings from its Australian oncology trial showing directional changes in extracellular vesicles, exosomes, microRNAs, and lymphocyte counts following Hemopurifier treatment in patients resistant to anti-PD-1 therapy...

This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda®...

Aethlon Medical a therapeutic medical device and technology company focused on unmet needs in oncology and viral diseases announced today that the National Institute for Dental and Craniofacial Research (NIDCR), a unit of the National Institutes for...

Aethlon Medical, Inc, a therapeutic medical device and technology company focused on unmet needs in global health, announced today that it has received..

Aethlon Medical, Inc, a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has received an Expedited Access Pathway (EAP) designation from the United States Food and Drug Administration (FDA) to support the ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the United States Patent and Trademark Office has granted U.S. Patent Number 9,707,333 (the ‘333 Patent), entitled “EXTRACORPOREAL REMOVAL ...

Interview on National Public Radio with Jim Joyce, CEO of Aethlon Medical and Executive Chairman of Exosome Sciences. Its blood test appears to identify CTE – Chronic Traumatic Encephalopathy – in retired NFL players. The interview is quite informative as ...

Results will add to Published Data Involving Candidate Biomarker to Identify & Monitor CTE Researchers with Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company, today announced plans to initiate a clinical study ...

SAN DIEGO, June 14, 2016 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that U.S. Patent Number 9,364,601 (the “601 Patent”), related to methods for capturing an exosome from a patient, has been issued to the Company by the ...

Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc., announced recently that it has agreed to participate in a clinical research study to establish methods for detecting and diagnosing chronic traumatic encephalopathy (CTE) during life as well as ...